A Study of the Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine in Subjects Aged 65 Years and Older

Sponsor

Sanofi Pasteur, a Sanofi Company (Industry)

Overall Status

Completed

CT.gov ID

NCT02553343

Collaborator

(none)

792

Enrollment

Locations

Arms

7.1

Duration (Months)

Patients Per Site

12.4

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

The aim of the study is to assess the safety and immunogenicity of two formulations of the high-dose quadrivalent influenza vaccine compared to the licensed high-dose trivalent influenza vaccine control in healthy elderly subjects aged 65 years of age and above.

Primary objectives:

To describe the safety profile of all subjects in each study group.
To demonstrate that the high-dose quadrivalent influenza vaccine induces an immune response (as assessed by HAI geometric mean titers (GMTs) that is non-inferior to responses induced by the licensed high-dose trivalent influenza vaccine for the 3 common virus strains at 28 days post-vaccination.

Secondary objectives:

To describe post-vaccination immunogenicity for the 4 virus strains (as assessed by seroconversion and seroprotection) for subjects who receive the high-dose quadrivalent influenza vaccine and the licensed high-dose trivalent influenza vaccine.
To describe post-vaccination immunogenicity for the 4 virus strains (as assessed by GMTs, seroconversion, and seroprotection) for subjects who receive the high-dose quadrivalent influenza vaccine and the investigational high-dose trivalent influenza vaccine.

Condition or Disease	Intervention/Treatment	Phase
Influenza	Biological: High-dose quadrivalent influenza virus vaccine Biological: High-dose influenza virus vaccine Biological: High-dose trivalent inactivated influenza vaccine Biological: High-dose trivalent inactivated influenza vaccine	Phase 2

Detailed Description

All eligible participants will be randomized to receive a single injection of either one of the high-dose quadrivalent influenza vaccine formulations or one of the high-dose trivalent influenza vaccines at Day 0. They will provide blood samples for hemagglutination inhibition (HAI) testing. Safety information as solicited, unsolicited reactions, serious adverse events, including adverse events of special interest will be collected in the trial.

Study Design

Study Type:

Interventional

Actual Enrollment :

792 participants

Allocation:

Randomized

Intervention Model:

Parallel Assignment

Masking:

Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

Primary Purpose:

Prevention

Official Title:

Safety and Immunogenicity Trial of High-Dose Quadrivalent Influenza Vaccine Administered by Intramuscular Route in Subjects Aged 65 Years and Older

Study Start Date :

Sep 1, 2015

Actual Primary Completion Date :

Apr 4, 2016

Actual Study Completion Date :

Apr 4, 2016

Arms and Interventions

Arm	Intervention/Treatment
Experimental: QIV HD1 Group Adults ≥ 65 years of age randomly assigned to receive an intramuscular injection of one dose of High-Dose quadrivalent influenza vaccine (formulation 1)	Biological: High-dose quadrivalent influenza virus vaccine 0.5 mL, Intramuscular (IM), injected into the deltoid area Other Names: High-dose quadrivalent influenza virus vaccine (QIV HD1)
Experimental: QIV HD2 Group Adults ≥ 65 years of age randomly assigned to receive an intramuscular injection of one dose of High-Dose quadrivalent influenza vaccine (formulation 2)	Biological: High-dose influenza virus vaccine 0.5 mL, Intramuscular (IM), injected into the deltoid area Other Names: High-dose quadrivalent influenza virus vaccine (QIV HD2)
Active Comparator: TIV HD1 Group Adults ≥ 65 years of age randomly assigned to receive an intramuscular injection of one dose of licensed High Dose trivalent influenza vaccine	Biological: High-dose trivalent inactivated influenza vaccine 0.5 mL, Intramuscular (IM), injected into the deltoid area Other Names: Fluzone® High-Dose, TIV HD1
Active Comparator: TIV HD2 Group Adults ≥ 65 years of age randomly assigned to receive an intramuscular injection of one dose of investigational High-Dose trivalent influenza vaccine	Biological: High-dose trivalent inactivated influenza vaccine 0.5 mL, Intramuscular (IM), injected into the deltoid area Other Names: TIV HD2

Outcome Measures

Primary Outcome Measures

Number of participants reporting solicited injection site and systemic events, unsolicited adverse events and serious adverse events following vaccination with a dose of Fluzone influenza vaccines [Day 0 up to 6 months post-vaccination]
Solicited injection site: Pain, Redness, Swelling, Induration, and Ecchymosis. Solicited systemic reaction: Fever (Temperature), Headache, Malaise, Myalgia, and Shivering. Unsolicited adverse events, including serious adverse events, will also be collected
Hemagglutination inhibition (HAI) antibody titers to influenza virus antigens following vaccination with Fluzone High Dose quadrivalent influenza vaccine or High Dose trivalent influenza vaccine [Day 28 post-vaccination]

Secondary Outcome Measures

Seroconversion with respect to vaccine antigens following vaccination with Fluzone High-dose quadrivalent influenza vaccine or High-dose trivalent influenza vaccine [Day 28 post-vaccination]
Seroconversion is defined as either a pre-vaccination titer < 10 (1/dil) and a post-vaccination titer ≥ 40 (1/dil), or a pre-vaccination titer ≥ 10 (1/dil) and a ≥ 4-fold increase in post-vaccination titer at 28 days after vaccination.
Seroprotection with respect to vaccine antigens following vaccination with Fluzone High-dose quadrivalent influenza vaccine or High-dose trivalent influenza vaccine [Day 28 post-vaccination]
Seroprotection is defined as a titer ≥ 40 (l/dil) at pre-vaccination and at 28 days after vaccination.

Eligibility Criteria

Criteria

Ages Eligible for Study:

65 Years and Older

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Yes

Inclusion Criteria:

Aged ≥ 65 years on the day of inclusion
Informed consent form has been signed and dated
Able to attend all scheduled visits and to comply with all trial procedures.

Exclusion Criteria:

Participation at the time of trial enrollment (or in the 4 weeks preceding the trial vaccination) or planned participation during the present trial period in another clinical trial investigating a vaccine, drug, medical device, or medical procedure
Receipt of any vaccine in the 4 weeks (28 days) preceding the trial vaccination or planned receipt of any vaccine prior to Visit 2
Vaccination against influenza in the past 6 months
Receipt of immune globulins, blood or blood-derived products in the past 3 months
Known or suspected congenital or acquired immunodeficiency; or receipt of immunosuppressive therapy, such as anti-cancer chemotherapy or radiation therapy, within the preceding 6 months; or long-term systemic corticosteroid therapy (prednisone or equivalent for more than 2 consecutive weeks within the past 3 months)
Known systemic hypersensitivity to any of the vaccine components, or history of a life-threatening reaction to the vaccine used in the trial or to a vaccine containing any of the same substances
Thrombocytopenia or bleeding disorder, contraindicating IM vaccination based on investigator's judgment
Deprived of freedom by an administrative or court order, or in an emergency setting, or hospitalized involuntarily
Substance abuse that, in the opinion of the investigator, might interfere with the trial conduct or completion
Chronic illness that, in the opinion of the investigator, is at a stage where it might interfere with trial conduct or completion
Identified as an Investigator or employee of the Investigator or trial center with direct involvement in the proposed trial, or identified as an immediate family member (i.e., parent, spouse) of the Investigator or employee with direct involvement in the proposed trial
Personal or family history of Guillain-Barré syndrome
Neoplastic disease or any hematologic malignancy (except localized skin or prostate cancer that is stable at the time of vaccination in the absence of therapy and subjects who have a history of neoplastic disease and have been disease free for ≥ 5 years)
Known allergy to iodinated radiocontrast media
Moderate or severe acute illness/infection (according to investigator judgment) on the day of vaccination or febrile illness (temperature ≥ 38.0°C [≥ 100.4°F]). A prospective subject should not be included in the trial until the condition has resolved or the febrile event has subsided.

Contacts and Locations

Locations

	City	State	Country	Postal Code
1	Milford	Connecticut	United States	06460
2	Coral Gables	Florida	United States	33134
3	Wichita	Kansas	United States	67207
4	Saint Louis	Missouri	United States	63104
5	Rochester	New York	United States	14609
6	Warwick	Rhode Island	United States	02886
7	Nashville	Tennessee	United States	37212
8	Salt Lake City	Utah	United States	84109
9	West Jordan	Utah	United States	84088